New treatment options for OCD

References

• American Psychiatric Association. Diagnostic and statistical manual of mental disorders IV. Washington, DC: American Psychiatric Association; 2004.
   Google Scholar
• Wittchen H-U, Jacobi F. Size and burden of mental disorders in Europe – a critical review and appraisal of 27 studies. Eur Neuropsychopharm 2005; 15: 257–376
   Google Scholar
• Pinto A, Mancebo MC, Eisen JL, Pagano ME, Rasmussen SA. The Brown Longitudinal Obsessive Compulsive Study: clinical features and symptoms of the sample at intake. J Clin Psychiatry 2006; 67(5)703–11
   PubMed Web of Science ®Google Scholar
• Heyman I, Fombonne E, Simmons H, Ford T, Meltzer H, Goodman R. Prevalence of obsessive-compulsive disorder in the British nationwide survey of child mental health. Br J Psychiatry 2001; 179: 324–9
   PubMed Web of Science ®Google Scholar
• Rasmussen SA, Eisen JL. The epidemiology and differential diagnosis of obsessive compulsive disorder. J Clin Psychiatr 1992; 53(Suppl): 4–10
   Google Scholar
• Lochner C, Hemmings SM, Kinnear CJ, et al. Gender in obsessive-compulsive disorder: clinical and genetic findings. Eur Neuropsychopharmacol 2004; 14(2)105–13
   Google Scholar
• Eisen JL, Mancebo MA, Pinto A, et al. Impact of obsessive compulsive disorder on quality of life. Compr Psychiatry 2006; 47: 270–5
   PubMed Web of Science ®Google Scholar
• Heyman I, Mataix-Cols D, Fineberg NA. Obsessive-compulsive behaviour. Br Med J 2006; 333: 424–9
   PubMed Web of Science ®Google Scholar
• Piggott TA, L'Heureux F, Bernstein S, et al. Obsessive compulsive disorder: comorbid conditions. J Clin Psychiatry 1994; 55(Suppl): 15–32
   Google Scholar
• Hollander E, Wong C. Psychosocial function and economic costs of obsessive compulsive disorder. CNS Spectr 1998; 3(Suppl 1)48–58
   Google Scholar
• National Collaborating Centre for Mental Health. Obsessive Compulsive Disorder: Guideline Accessed at, , http://www.nccmh.org.uk/Guidelines/Guidelines_by_topic/OCD_Guideline.php ( February 2007).
   Google Scholar
• The British Psychological Society and the Royal College of Psychiatrists, UK. The NICE Guideline for Obsessive Compulsive Disorder: core interventions in the treatment of obsessive compulsive disorder and body dysmorphic disorder. 2006.
   Google Scholar
• Piccinelli M, Pini S, Bellantuono C, Wilkinson G. Efficacy of drug treatment in obsessive compulsive disorder. A meta-analytic review. Br J Psychiatr 1995; 166: 424–43
   PubMed Web of Science ®Google Scholar
• Fineberg NA, Roberts A, Montgomery SA, Cowen PH. Brain 5-HT function in obsessive-compulsive disorder: prolactin responses to d-fenfluramine. Br J Pschiatry 1997; 171: 280–2
   Google Scholar
• Flament MF, Rapoport JL, Berg CJ, et al. Clomipramine treatment of childhood obsessive-compulsive disorder. A double-blind controlled study. Arch Gen Psychiatry 1985; 42(10)977–83
   PubMed Web of Science ®Google Scholar
• Insel TR, Murphy DL, Cohen RM, et al. Obsessive-compulsive disorder–a double-blind trial of clomipramine and clorgyline. Arch of Gen Psychiatr 1983; 40: 605–12
   PubMed Web of Science ®Google Scholar
• Mavissakalian M, Turner SM, Michelson L, Jacob R. Tricyclic antidepressants in obsessive-compulsive disorder: antiobsessional or antidepressant agents? II. Am J Psychiatr 1985; 142: 572–6
   PubMed Web of Science ®Google Scholar
• Katz RJ, De Veaugh-Geiss J, Landau P. Clomipramine in obsessive compulsive disorder. Biol Psychiatr 1990; 28: 401–4
   PubMed Web of Science ®Google Scholar
• Marks IM, Lelliott P, Basoglu M, et al. Clomipramine, self-exposure and therapist-aided exposure for obsessive-compulsive rituals. Br J Psychiatr 1988; 152: 522–34
   PubMed Web of Science ®Google Scholar
• Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 1989; 46(11)1006–11
   PubMed Web of Science ®Google Scholar
• The Clomipramine Collaborative Study Group. Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 1991;48:730–8.
   PubMed Web of Science ®Google Scholar
• Fineberg NA, Gale TM. Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int J Neuropsychopharmacol 2005; 8(1)107–29
   Web of Science ®Google Scholar
• Lopez-Ibor JJ, Saiz J, Cottraux J, et al. Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder. Eur Neuropsychopharm 1996; 6: 111–8
   PubMed Web of Science ®Google Scholar
• Guy, W. In: ECDEU assessment manual for psychopharmacology. 2nd ed. Washington, DC: US Government Printing Office, US Dept Health, Education, and Welfare publication, (ADM) 76–338. Rockville, MD: National Institute of Mental Health; 1976.
   Google Scholar
• Bisserbe, JC, Lane, RM, Flament, MF, and the Franco-Belgian OCD study group. A double-blind comparison of sertraline and clomipramine in outpatients with obsessive-compulsive disorder. Eur Psychiatr 1997;12:82–93.
   PubMed Web of Science ®Google Scholar
• March, JS, Mulle, K. National Institute of Mental Health Global Obsessive Compulsive Scale; OCD in children and adolescents; 1998 ( ISBN: 1-57230-242-9).
   Google Scholar
• Mundo E, Rouillon F, Figuera ML, Sigler M. Fluvoxamine in obsessive-compulsive disorder: similar efficacy but superior tolerability in comparison with clomipramine. Hum Psychopharmacol 2001; 16: 461–8
   PubMed Web of Science ®Google Scholar
• Zohar J, Judge R. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators. Br J Psychiatry 1996; 169(4)468–74
   PubMed Web of Science ®Google Scholar
• March JS, Leonard HL. Obsessive-compulsive disorder in children and adolescents: a review of the past 10 years. J Am Acad Child Adolesc Psychiatry 1996; 35(10)1265–73
   PubMed Web of Science ®Google Scholar
• Hollander E, Allen A, Steiner M, et al. Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. J Clin Psychiatr 2003; 64: 1113–21
   PubMed Web of Science ®Google Scholar
• Montgomery SA, McIntyre A, Osterheider M, et al. A double-blind placebo-controlled study of fluoxetine in patients with DSM-IIIR obsessive compulsive disorder. Eur Neuropsychopharmacol 1993; 3: 143–52
   PubMedGoogle Scholar
• Tollefson G, Rampey A, Potvin J, et al. A multicentre investigation of fixed-dose fluoxetine in the treatment of obsessive compulsive disorder. Arch Gen Psychiatr 1994; 51: 559–67
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Kasper S, Stein DJ, et al. Citalopram 20 mg, 40 mg, and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. Int Clin Psychopharmacol 2001; 16: 75–86
   PubMed Web of Science ®Google Scholar
• Greist JH, Jefferson JW, Koback KA, et al. A one year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive compulsive disorder. Int Clin Psychopharmacol 1995; 10: 57–65
   PubMed Web of Science ®Google Scholar
• Ushijima S, Kamijima K, Asai M, et al. Clinical evaluation of sertraline, a selective serotonin reuptake inhibitor, in the treatment of obsessive-compulsive disorder: a double-blind placebo-controlled trial. Jpn J Neuropsychopharmacol 1997; 19: 603–23
   Google Scholar
• Greist JH, Bandelow B, Hollander E, et al. World Council of Anxiety. WCA recommendations for the long-term treatment of obsessive-compulsive disorder in adults. CNS Spectr 2003; 8(Suppl 1)7–16
   Google Scholar
• Baldwin DS, Anderson IM, Nutt DJ, et al. British Association for Psychopharmacology. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2006a; 19(6)567–96
   Google Scholar
• Cook EH, Wagner KD, March JS, et al. Long-term sertraline treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 2001; 40(10)1175–81
   Google Scholar
• Rasmussen S, Hackett E, Duboff E, et al. A 2-year study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 1997; 12: 309–16
   PubMed Web of Science ®Google Scholar
• Pato MT, Zohar-Kadouch R, Zohar J. Return of symptoms after discontinuation of clomipramine in patients with obsessive compulsive disorder. Am J Psych 1988; 145: 211–4
   Google Scholar
• Leonard HL, Swedo S, Rapoport JL, Coffey M, Cheslow D. Treatment of childhood obsessive compulsive disorder with clomipramine and desmethylimipramine: a double-blind crossover comparison. Psychopharmacol Bull 1988; 24: 93–5
   PubMed Web of Science ®Google Scholar
• Yaryura-Tobias JA, Neziroglu FA. Venlafaxine in obsessive-compulsive disorder. Arch Gen Psychiatry 1996; 53(7)653–4
   Google Scholar
• Romano S, Goodman W, Tamura R, Gonzales J. Long-term treatment of obsessive-compulsive disorder after an acute response: a comparison of fluoxetine versus placebo. J Clin Psychopharmacol 2001; 21: 46–52
   PubMed Web of Science ®Google Scholar
• Koran L, Hackett E, Rubin A, et al. Efficacy of sertraline in the long-term treatment of obsessive compulsive disorder. Am J Psychiatr 2002; 159: 88–95
   PubMed Web of Science ®Google Scholar
• Thase ME. Managing depressive and anxiety disorders with escitalopram. Expert Opin Pharmacother 2006; 7(4)429–40
   PubMed Web of Science ®Google Scholar
• Murdoch D, Keam SJ. Escitalopram: a review of its use in the management of major depressive disorder. Drugs 2005; 65(16)2379–404
   Google Scholar
• Lader M, Stender K, Burger V, Nil R. Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety 2004; 19(4)241–8
   PubMed Web of Science ®Google Scholar
• Baldwin DS, Huusom AK, Maehlum E. Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study. Br J Psychiatry 2006b; 189: 264–72
   PubMed Web of Science ®Google Scholar
• Dhillon S, Scott LJ, Plosker GL. Escitalopram: a review of its use in the management of anxiety disorders. CNS Drugs 2006; 20: 763–90
   PubMed Web of Science ®Google Scholar
• Rampello L, Alvano A, Raffaele R, Malaguarnera M, Vecchio I. New possibilities of treatment for panic attacks in elderly patients: escitalopram versus citalopram. J Clin Psychopharmacol 2006; 26(1)67–70
   Google Scholar
• Stein, D, Tonnoir, B, Andersen, EW, Fineberg, N. Escitalopram in the treatment of obsessive-compulsive disorder. Poster presented at the Annual Meeting of the American Psychiatric Association, 20–25, May, 2006, Toronto, Canada.
   Google Scholar
• Montgomery SA, Asberg M. A new depression rating scale designed to be sensitive to change. Br J Psychiatr 1979; 134: 382–9
   PubMed Web of Science ®Google Scholar
• Fineberg, N, Lemming, O, Tonnoir, B, Stein, D. Escitalopram in relapse prevention in patients with obsessive-compulsive disorder (OCD). Poster presented at the Annual meeting of the American Psychiatric Association, 20–25, May, 2006, Toronto, Canada.
   Google Scholar